NEW ORLEANS — Filip Janku, MD, PhD, medical oncologist at The University of Texas MD Anderson Cancer Center, spoke to HemOnc Today about the clinical utility of liquid biopsies.
Janku discussed how liquid biopsies can help detect underlying genomic alterations, monitor patients’ response to therapies and enhance understanding of therapy resistance. However, they likely will remain complimentary to tissue biopsies, Janku said.
“I personally don’t believe that liquid biopsies will replace cancer tissue,” Janku told HemOnc Today. “Cancer biopsies and analysis of the cancer tissue will remain important, but I can also see liquid biopsies as another modality that will simply help us get more information that will help us to treat our patients better and in a more informational way.”